Phaseline

Targets › PABPC1

PABPC1 (Polyadenylate-binding protein 1): drug programs, companies and trials

1 program from 1 company in 2 trials: 2 Phase 2; Genitourinary, Oncology; next expected readout Sep 2027.

Binds the poly(A) tail of mRNA, including that of its own transcript, and regulates processes of mRNA metabolism such as pre-mRNA splicing and mRNA stability. Its function in translational initiation regulation can either be enhanced by PAIP1 or repressed by PAIP2. (UniProt, P11940)

Open in Phaseline: the race on PABPC1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
baotai LiangHomoharringtonine
Translation inhibitor; binds eukaryotic ribosomal 80S subunit to inhibit protein synthesis
PABPC1Phase 2Prostate Cancer; Prostate CASep 2027

Conditions

Prostate Cancer (1) Prostate CA (1)

Modalities

small molecule (1)

Companies

baotai Liang (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.